Announcement • Jun 12

C4 Therapeutics Presents Phase 1 Data At European Hematology Association 2026 Congress Highlighting Cemsidomide as A Potential Best-In-Class Ikzf1/3 Degrader for Multiple Myeloma in Heavily Pretreated Relapsed/Refractory Population

C4 Therapeutics, Inc. will present further analysis from its fully enrolled Phase 1 trial of cemsidomide, a next-generation oral IKZF1/3 degrader, in combination with dexamethasone for the treatment of relapsed/refractory multiple myeloma (RRMM) in a poster presentation at the European Hematology Association (EHA) 2026 Congress on Friday, June 12, 2026 at 6:45 pm CEST /12:45 pm ET. The analysis is consistent with previous data disclosed from the Phase 1 clinical trial and highlights cemsidomide's anti-myeloma activity and differentiated safety profile, further supporting its development as a potential best-in-class IKF1/3 degrader. The poster will be presented by Sagar Lonial, M.D., FACP, FASCO, chief medical officer at the Winship Cancer Institute at Emory University, and an investigator in the cemsidomide clinical trials. The poster presentation includes data on 73 patients with a data cutoff of February 27, 2026. Patients were heavily pretreated, receiving a median of seven prior lines of therapy. Fifty-five patients (75%) received prior BCMA therapy, and 55 patients (75%) received prior CAR-T or T-cell engager therapy (TCE). At the RP2D and maximum tolerated dose (100 µg,) cemsidomide achieved a 53% overall response rate (ORR). At the 75 µg dose level, cemsidomide achieved a 40% ORR. Across all doses evaluated, cemsidomide achieved a 36% ORR. Key new data include: Responses deepened over time across the cemsidomide 75 µg and 100 µg dose levels: At 75 µg, one patient whose best response was previously a partial response (PR) deepened to a very good partial response (VGPR). At 100 µg, several patients achieved a deeper response: One patient whose best response was previously a PR deepened to a stringent complete response (sCR). One patient whose best response was previously a PR deepened to a VGPR. Minimal residual disease (MRD) negativity was achieved in two patients who achieved a sCR and complete response (CR) at 100 µg. ORR was consistent across key subgroups. Durable responses were observed across all dose levels: Patients experienced a median duration of response of 7.9 months (95% CI, 3.0 – non-evaluable). Seven patients remain on treatment currently. Cemsidomide in combination with dexamethasone was generally well tolerated. Incidences of on-target neutropenia remained manageable; 42 patients (58%) experienced Grade 3/4 neutropenia. All treatment emergent adverse events were manageable with no discontinuations deemed related to cemsidomide and minimal dose reductions (five patients; 7%).

C4 Therapeutics, Inc. Stock Price

CCCC Share Price Performance

CCCC Community Narratives

Trending Discussion

Recently Updated Narratives

Snowflake Analysis

C4 Therapeutics, Inc. Key Details

About CCCC

Recent CCCC News & Updates

C4 Therapeutics Presents Phase 1 Data At European Hematology Association 2026 Congress Highlighting Cemsidomide as A Potential Best-In-Class Ikzf1/3 Degrader for Multiple Myeloma in Heavily Pretreated Relapsed/Refractory Population

Price target increased by 15% to US$13.33

C4 Therapeutics "Buy" On Cemsidomide Advancement And Competitor's Positive Readout

Recent updates

C4 Therapeutics, Inc. Competitors

Inhibrx Biosciences

BioLife Solutions

Avalyn Pharma

Perrigo